US Patent Issued to Janssen Biotech on Oct. 21 for "Combination therapies with bispecific anti-EGFR/c-met antibodies and third generation EGFR tyrosine kinase inhibitors" (Pennsylvania Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,448,455, issued on Oct. 21, was assigned to Janssen Biotech Inc. (Horsham, Pa.).

"Combination therapies with bispecific anti-EGFR/c-met antibodies and third generation EGFR tyrosine kinase inhibitors" was invented by Sylvie Laquerre (Chesterbrook, Pa.), Matthew Lorenzi (Philadelphia) and Sheri Moores (Wayne, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to combination therapies with bispecific anti-EGFR/c-Met antibodies and 3rd generation EGFR tyrosine kinase inhibitors."

The patent was filed on Nov. 15, 2023, under Application No. 18/510,412.

*For further information, including images, charts and tables, please visi...